. 2006 Jan 10;94(2):189–194. doi: 10.1038/sj.bjc.6602917

Table 1. Description of the prospective studies on thromboprophylaxis for cancer patients with CVC included in this review.

Study	n	Catheter	Location	Intervention	Duration	Test	Objective VTE	Symptomatic VTE
Bozzetti et al (1983)¹⁵ (cohort study)	52	External	Subclavian	Heparin 2500–3100 U daily	6–38 days	Venogram	Heparin 5/15 (33%) Control 10/37 (27%)	Heparin 0/15 (0%)
Bern et al (1990)¹⁶ (open randomised study)	121	Port	Subclavian	Warfarin 1 mg daily	90 days	Venogram	Warfarin 4/42 (10%) Control 15/40 (38%)	Warfarin 4/42 (10%) Control 10/40 (25%)
Monreal et al (1996)¹⁷ (open randomised study)	32	Port	Subclavian	Fragmin 2500 IU s.c. once daily	90 days	Venogram	Fragmin 1/16 (6%) Control 8/13 (62%)	Not specified
Nightingale et al (1997)¹⁸ (cohort study)	832	External	Sublavian+ jugular+femoral	Warfarin 1 mg daily	Mean 122 days	Ultrasound± venogram	Symptomatic only	Warfarin 42/949 (4%)
Boraks et al (1998)¹⁹ (cohort study)	108	External	Subclavian	Warfarin 1 mg daily	Catheter duration	Ultrasound± venogram	Symptomatic only	Warfarin 5/108 (5%) (historical controls)
Heaton et al (2002)²⁰ (open randomised study)	88	External	Subclavian	Warfarin 1 mg daily	90 days	Venogram	Warfarin 8/45 (18%) Control 5/43 (12%)	Not specified
Mismetti et al (2003)²¹ (open randomised study)	59	Port	Subclavian+ jugular	Nadroparin 2850U or warfarin 1 mg	90 days	Venogram	Nadroparin 6/21 (29%) warfarin 4/24 (17%)	Nadroparin 1/21 (5%) Warfarin 2/24 (8%)
Couban et al (2005)²² (placebo RCT)	255	Port+ External	Sublavian+ jugular	Warfarin 1 mg or placebo	Catheter duration	Ultrasound± venogram	Symptomatic only	Warfarin 6/130 (5%) Placebo 5/125 (4%)
Verso et al (2005)²³ (placebo RCT)	385	External	Sublavian+ jugular	Enoxaparin 40 mg or placebo	42 days	Venogram	Enoxaparin 22/155 (14%) Placebo 28/155 (18%)	Enoxaparin 2/155 (1%) Placebo 6/155 (3%)